Recently, clinical trials of tirzepatide, a dual GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, have achieved approximately 20% weight loss in substantial proportions of people with obesity (1). Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.